Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
November 16, 2021 07:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
November 02, 2021 07:00 ET
|
Voyager Therapeutics, Inc.
License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestone payments plus royalties in exchange for access to TRACER™ novel capsids for...
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
October 20, 2021 08:54 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus...
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
October 06, 2021 07:00 ET
|
Voyager Therapeutics, Inc.
Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties Pfizer receives transgene-specific access to...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
September 02, 2021 17:08 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies,...
Voyager Therapeutics to Participate in Upcoming Investor Conferences
August 10, 2021 16:20 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies,...
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies
August 09, 2021 07:00 ET
|
Voyager Therapeutics, Inc.
Proprietary AAV capsids to power second-generation efforts in Huntington’s disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations Increased platform...
Voyager Therapeutics Announces Strategic Shift and Leadership Transitions
May 19, 2021 16:01 ET
|
Voyager Therapeutics, Inc.
Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington’s disease and maximizing opportunities created by TRACERTM gene therapy technology platform and next-generation...
Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
May 12, 2021 07:30 ET
|
Voyager Therapeutics, Inc.
Findings to be presented at the 24th Annual Meeting of the American Society of Gene and Cell Therapy Data demonstrate durable expression in CNS and may represent a new single-dose therapeutic...
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates
May 11, 2021 07:30 ET
|
Voyager Therapeutics, Inc.
Data to be presented at the 24th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene...